1
|
Mrksich K, Padilla MS, Mitchell MJ. Breaking the final barrier: Evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome. Adv Drug Deliv Rev 2024:115446. [PMID: 39293650 DOI: 10.1016/j.addr.2024.115446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2024] [Revised: 08/18/2024] [Accepted: 09/07/2024] [Indexed: 09/20/2024]
Abstract
In the past decade, nucleic acid therapies have seen a boon in development and clinical translation largely due to advances in nanotechnology that have enabled their safe and targeted transport. Nanoparticles can protect nucleic acids from degradation by serum enzymes and can facilitate entry into cells. Still, achieving endosomal escape to allow the nucleic acids to enter the cytoplasm has remained a significant barrier, where less than 5% of particles within the endo-lysosomal pathway are able to transfer their cargo to the cytosol. Lipid-based drug delivery vehicles, particularly lipid nanoparticles (LNPs), have been optimized to achieve potent endosomal escape, and thus have been the vector of choice in the clinic as demonstrated by their utilization in the COVID-19 mRNA vaccines. The success of LNPs is in large part due to the rational design of lipids that can specifically break through endosomal barriers. In this review, we chart the evolution of lipid structure from cationic lipids to ionizable lipids, focusing on structure-function relationships, especially as they relate to endosomal escape. Additionally, we examine recent advancements in ionizable lipid structure as well as discuss the future of lipid design.
Collapse
Affiliation(s)
- Kaitlin Mrksich
- Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Marshall S Padilla
- Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Michael J Mitchell
- Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, PA 19104, USA; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Penn Institute for RNA Innovation, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
| |
Collapse
|
2
|
Taghdiri M, Mussolino C. Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets. Int J Mol Sci 2024; 25:7333. [PMID: 39000440 PMCID: PMC11242246 DOI: 10.3390/ijms25137333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2024] [Revised: 06/10/2024] [Accepted: 06/24/2024] [Indexed: 07/16/2024] Open
Abstract
Clustered regularly interspersed short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology has revolutionized the field of gene therapy as it has enabled precise genome editing with unprecedented accuracy and efficiency, paving the way for clinical applications to treat otherwise incurable genetic disorders. Typically, precise genome editing requires the delivery of multiple components to the target cells that, depending on the editing platform used, may include messenger RNA (mRNA), protein complexes, and DNA fragments. For clinical purposes, these have to be efficiently delivered into transplantable cells, such as primary T lymphocytes or hematopoietic stem and progenitor cells that are typically sensitive to exogenous substances. This challenge has limited the broad applicability of precise gene therapy applications to those strategies for which efficient delivery methods are available. Electroporation-based methodologies have been generally applied for gene editing applications, but procedure-associated toxicity has represented a major burden. With the advent of novel and less disruptive methodologies to deliver genetic cargo to transplantable cells, it is now possible to safely and efficiently deliver multiple components for precise genome editing, thus expanding the applicability of these strategies. In this review, we describe the different delivery systems available for genome editing components, including viral and non-viral systems, highlighting their advantages, limitations, and recent clinical applications. Recent improvements to these delivery methods to achieve cell specificity represent a critical development that may enable in vivo targeting in the future and will certainly play a pivotal role in the gene therapy field.
Collapse
Affiliation(s)
- Maryam Taghdiri
- Institute for Transfusion Medicine and Gene Therapy, Medical Center-University of Freiburg, 79106 Freiburg, Germany
- Center for Chronic Immunodeficiency (CCI), Medical Center-University of Freiburg, 79106 Freiburg, Germany
- Ph.D. Program, Faculty of Biology, University of Freiburg, 79106 Freiburg, Germany
| | - Claudio Mussolino
- Institute for Transfusion Medicine and Gene Therapy, Medical Center-University of Freiburg, 79106 Freiburg, Germany
- Center for Chronic Immunodeficiency (CCI), Medical Center-University of Freiburg, 79106 Freiburg, Germany
- Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany
| |
Collapse
|
3
|
Dekevic G, Tertel T, Tasto L, Schmidt D, Giebel B, Czermak P, Salzig D. A Bioreactor-Based Yellow Fever Virus-like Particle Production Process with Integrated Process Analytical Technology Based on Transient Transfection. Viruses 2023; 15:2013. [PMID: 37896790 PMCID: PMC10612092 DOI: 10.3390/v15102013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 09/21/2023] [Accepted: 09/22/2023] [Indexed: 10/29/2023] Open
Abstract
Yellow Fever (YF) is a severe disease that, while preventable through vaccination, lacks rapid intervention options for those already infected. There is an urgent need for passive immunization techniques using YF-virus-like particles (YF-VLPs). To address this, we successfully established a bioreactor-based production process for YF-VLPs, leveraging transient transfection and integrating Process Analytical Technology. A cornerstone of this approach was the optimization of plasmid DNA (pDNA) production to a yield of 11 mg/L using design of experiments. Glucose, NaCl, yeast extract, and a phosphate buffer showed significant influence on specific pDNA yield. The preliminary work for VLP-production in bioreactor showed adjustments to the HEK cell density, the polyplex formation duration, and medium exchanges effectively elevated transfection efficiencies. The additive Pluronic F-68 was neutral in its effects, and anti-clumping agents (ACA) adversely affected the transfection process. Finally, we established the stirred-tank bioreactor process with integrated dielectric spectroscopy, which gave real-time insight in relevant process steps, e.g., cell growth, polyplex uptake, and harvest time. We confirmed the presence and integrity of YF-VLP via Western blot, imaging flow cytometry measurement, and transmission electron microscopy. The YF-VLP production process can serve as a platform to produce VLPs as passive immunizing agents against other neglected tropical diseases.
Collapse
Affiliation(s)
- Gregor Dekevic
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen, Wiesenstrasse 14, 35390 Giessen, Germany; (G.D.); (L.T.); (D.S.); (P.C.)
| | - Tobias Tertel
- Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Virchowstrasse 179, 45147 Essen, Germany; (T.T.); (B.G.)
| | - Lars Tasto
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen, Wiesenstrasse 14, 35390 Giessen, Germany; (G.D.); (L.T.); (D.S.); (P.C.)
| | - Deborah Schmidt
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen, Wiesenstrasse 14, 35390 Giessen, Germany; (G.D.); (L.T.); (D.S.); (P.C.)
| | - Bernd Giebel
- Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Virchowstrasse 179, 45147 Essen, Germany; (T.T.); (B.G.)
| | - Peter Czermak
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen, Wiesenstrasse 14, 35390 Giessen, Germany; (G.D.); (L.T.); (D.S.); (P.C.)
- Faculty of Biology and Chemistry, University of Giessen, Heinrich-Buff-Ring 17, 35392 Giessen, Germany
| | - Denise Salzig
- Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen, Wiesenstrasse 14, 35390 Giessen, Germany; (G.D.); (L.T.); (D.S.); (P.C.)
| |
Collapse
|
4
|
Sun B, Wu W, Narasipura EA, Ma Y, Yu C, Fenton OS, Song H. Engineering nanoparticle toolkits for mRNA delivery. Adv Drug Deliv Rev 2023; 200:115042. [PMID: 37536506 DOI: 10.1016/j.addr.2023.115042] [Citation(s) in RCA: 18] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Revised: 07/26/2023] [Accepted: 07/31/2023] [Indexed: 08/05/2023]
Abstract
The concept of using mRNA to produce its own medicine in situ in the body makes it an ideal drug candidate, holding great potential to revolutionize the way we approach medicine. The unique characteristics of mRNA, as well as its customizable biomedical functions, call for the rational design of delivery systems to protect and transport mRNA molecules. In this review, a nanoparticle toolkit is presented for the development of mRNA-based therapeutics from a drug delivery perspective. Nano-delivery systems derived from either natural systems or chemical synthesis, in the nature of organic or inorganic materials, are summarised. Delivery strategies in controlling the tissue targeting and mRNA release, as well as the role of nanoparticles in building and boosting the activity of mRNA drugs, have also been introduced. In the end, our insights into the clinical and translational development of mRNA nano-drugs are presented.
Collapse
Affiliation(s)
- Bing Sun
- Australian Institute for Bioengineering and Nanotechnology, the University of Queensland, Brisbane, QLD 4072, Australia
| | - Weixi Wu
- Australian Institute for Bioengineering and Nanotechnology, the University of Queensland, Brisbane, QLD 4072, Australia
| | - Eshan A Narasipura
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Yutian Ma
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Chengzhong Yu
- Australian Institute for Bioengineering and Nanotechnology, the University of Queensland, Brisbane, QLD 4072, Australia
| | - Owen S Fenton
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
| | - Hao Song
- Australian Institute for Bioengineering and Nanotechnology, the University of Queensland, Brisbane, QLD 4072, Australia.
| |
Collapse
|
5
|
Kandil R, Baldassi D, Böhlen S, Müller JT, Jürgens DC, Bargmann T, Dehmel S, Xie Y, Mehta A, Sewald K, Merkel OM. Targeted GATA3 knockdown in activated T cells via pulmonary siRNA delivery as novel therapy for allergic asthma. J Control Release 2023; 354:305-315. [PMID: 36634709 PMCID: PMC7614985 DOI: 10.1016/j.jconrel.2023.01.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Revised: 12/20/2022] [Accepted: 01/06/2023] [Indexed: 01/14/2023]
Abstract
GATA3 gene silencing in activated T cells displays a promising option to early-on undermine pathological pathways in the disease formation of allergic asthma. The central transcription factor of T helper 2 (Th2) cell cytokines IL-4, IL-5, and IL-13 plays a major role in immune and inflammatory cascades underlying asthmatic processes in the airways. Pulmonary delivery of small interfering RNAs (siRNA) to induce GATA3 knockdown within disease related T cells of asthmatic lungs via RNA interference (RNAi) presents an auspicious base to realize this strategy, however, still faces some major hurdles. Main obstacles for successful siRNA delivery in general comprise stability and targeting issues, while in addition the transfection of T cells presents a particularly challenging task itself. In previous studies, we have developed and advanced an eligible siRNA delivery system composed of polyethylenimine (PEI) as polycationic carrier, transferrin (Tf) as targeting ligand and melittin (Mel) as endosomolytic agent. Resulting Tf-Mel-PEI polyplexes exhibited ideal characteristics for targeted siRNA delivery to activated T cells and achieved efficient and sequence-specific gene knockdown in vitro. In this work, the therapeutic potential of this carrier system was evaluated in an optimized cellular model displaying the activated status of asthmatic T cells. Moreover, a suitable siRNA sequence combination was found for effective gene silencing of GATA3. To confirm the translatability of our findings, Tf-Mel-PEI polyplexes were additionally tested ex vivo in activated human precision-cut lung slices (PCLS). Here, the formulation showed a safe profile as well as successful delivery to the lung epithelium with 88% GATA3 silencing in lung explants. These findings support the feasibility of Tf-Mel-PEI as siRNA delivery system for targeted gene knockdown in activated T cells as a potential novel therapy for allergic asthma.
Collapse
Affiliation(s)
- Rima Kandil
- Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University of Munich, Butenandtstraße 5, 81377 Munich, Germany
| | - Domizia Baldassi
- Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University of Munich, Butenandtstraße 5, 81377 Munich, Germany
| | - Sebastian Böhlen
- Fraunhofer Institute of Toxicology and Experimental Medicine, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH) of the German Center for Lung Research (DZL), Hannover, Germany
| | - Joschka T Müller
- Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University of Munich, Butenandtstraße 5, 81377 Munich, Germany
| | - David C Jürgens
- Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University of Munich, Butenandtstraße 5, 81377 Munich, Germany
| | - Tonia Bargmann
- Fraunhofer Institute of Toxicology and Experimental Medicine, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH) of the German Center for Lung Research (DZL), Hannover, Germany
| | - Susann Dehmel
- Fraunhofer Institute of Toxicology and Experimental Medicine, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH) of the German Center for Lung Research (DZL), Hannover, Germany
| | - Yuran Xie
- Department of Oncology, Wayne State University School of Medicine, 4100 John R St, Detroit, MI 48201, United States
| | - Aditi Mehta
- Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University of Munich, Butenandtstraße 5, 81377 Munich, Germany; Comprehensive Pneumology Center (CPC) with the CPC-M bioArchive, Helmholtz Munich, German Center for Lung Research (DZL), Munich, Germany
| | - Katherina Sewald
- Fraunhofer Institute of Toxicology and Experimental Medicine, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH) of the German Center for Lung Research (DZL), Hannover, Germany
| | - Olivia M Merkel
- Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University of Munich, Butenandtstraße 5, 81377 Munich, Germany; Comprehensive Pneumology Center (CPC) with the CPC-M bioArchive, Helmholtz Munich, German Center for Lung Research (DZL), Munich, Germany.
| |
Collapse
|
6
|
Lee M, Rice-Boucher PJ, Collins LT, Wagner E, Aulisa L, Hughes J, Curiel DT. A Novel Piggyback Strategy for mRNA Delivery Exploiting Adenovirus Entry Biology. Viruses 2022; 14:v14102169. [PMID: 36298724 PMCID: PMC9608319 DOI: 10.3390/v14102169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Revised: 09/20/2022] [Accepted: 09/22/2022] [Indexed: 12/01/2022] Open
Abstract
Molecular therapies exploiting mRNA vectors embody enormous potential, as evidenced by the utility of this technology for the context of the COVID-19 pandemic. Nonetheless, broad implementation of these promising strategies has been restricted by the limited repertoires of delivery vehicles capable of mRNA transport. On this basis, we explored a strategy based on exploiting the well characterized entry biology of adenovirus. To this end, we studied an adenovirus-polylysine (AdpL) that embodied "piggyback" transport of the mRNA on the capsid exterior of adenovirus. We hypothesized that the efficient steps of Ad binding, receptor-mediated entry, and capsid-mediated endosome escape could provide an effective pathway for transport of mRNA to the cellular cytosol for transgene expression. Our studies confirmed that AdpL could mediate effective gene transfer of mRNA vectors in vitro and in vivo. Facets of this method may offer key utilities to actualize the promise of mRNA-based therapeutics.
Collapse
Affiliation(s)
- Myungeun Lee
- Division of Cancer Biology, Department of Radiation Oncology, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA
| | - Paul J. Rice-Boucher
- Division of Cancer Biology, Department of Radiation Oncology, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA
- Department of Biomedical Engineering, McKelvey School of Engineering, Washington University in Saint Louis, St. Louis, MO 63130, USA
| | - Logan Thrasher Collins
- Division of Cancer Biology, Department of Radiation Oncology, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA
- Department of Biomedical Engineering, McKelvey School of Engineering, Washington University in Saint Louis, St. Louis, MO 63130, USA
| | - Ernst Wagner
- Department of Chemistry and Pharmacy, Ludwig-Maximilians-University (LMU), 81377 Munich, Germany
| | - Lorenzo Aulisa
- GreenLight Biosciences, Inc., 200 Boston Ave. #3100, Medford, MA 02155, USA
| | - Jeffrey Hughes
- GreenLight Biosciences, Inc., 200 Boston Ave. #3100, Medford, MA 02155, USA
| | - David T. Curiel
- Division of Cancer Biology, Department of Radiation Oncology, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA
- Biologic Therapeutics Center, Department of Radiation Oncology, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA
- Correspondence: ; Tel.: +1-314-747-5443; Fax: +1-314-362-9790
| |
Collapse
|
7
|
Vetter VC, Wagner E. Targeting nucleic acid-based therapeutics to tumors: Challenges and strategies for polyplexes. J Control Release 2022; 346:110-135. [PMID: 35436520 DOI: 10.1016/j.jconrel.2022.04.013] [Citation(s) in RCA: 23] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Revised: 04/07/2022] [Accepted: 04/10/2022] [Indexed: 12/18/2022]
Abstract
The current medical reality of cancer gene therapy is reflected by more than ten approved products on the global market, including oncolytic and other viral vectors and CAR T-cells as ex vivo gene-modified cell therapeutics. The development of synthetic antitumoral nucleic acid therapeutics has been proceeding at a lower but steady pace, fueled by a plethora of alternative nucleic acid platforms (from various antisense oligonucleotides, siRNA, microRNA, lncRNA, sgRNA, to larger mRNA and DNA) and several classes of physical and chemical delivery technologies. This review summarizes the challenges and strategies for tumor-targeted nucleic acid delivery. Focusing primarily on polyplexes (polycation complexes) as nanocarriers, delivery options across multiple barriers into tumor cells are illustrated.
Collapse
Affiliation(s)
- Victoria C Vetter
- Pharmaceutical Biotechnology, Center for System-based Drug Research, Ludwig-Maximilians-Universität, Munich 81377, Germany
| | - Ernst Wagner
- Pharmaceutical Biotechnology, Center for System-based Drug Research, Ludwig-Maximilians-Universität, Munich 81377, Germany; Center for NanoScience (CeNS), Ludwig-Maximilians-Universität, Munich 81377, Germany.
| |
Collapse
|
8
|
Dekevic G, Tasto L, Czermak P, Salzig D. Statistical experimental designs to optimize the transient transfection of HEK 293 T cells and determine a transfer criterion from adherent cells to larger-scale cell suspension cultures. J Biotechnol 2022; 346:23-34. [DOI: 10.1016/j.jbiotec.2022.01.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 12/20/2021] [Accepted: 01/15/2022] [Indexed: 02/04/2023]
|
9
|
Freitag F, Wagner E. Optimizing synthetic nucleic acid and protein nanocarriers: The chemical evolution approach. Adv Drug Deliv Rev 2021; 168:30-54. [PMID: 32246984 DOI: 10.1016/j.addr.2020.03.005] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2019] [Revised: 02/10/2020] [Accepted: 03/30/2020] [Indexed: 12/20/2022]
Abstract
Optimizing synthetic nanocarriers is like searching for a needle in a haystack. How to find the most suitable carrier for intracellular delivery of a specified macromolecular nanoagent for a given disease target location? Here, we review different synthetic 'chemical evolution' strategies that have been pursued. Libraries of nanocarriers have been generated either by unbiased combinatorial chemistry or by variation and novel combination of known functional delivery elements. As in natural evolution, definition of nanocarriers as sequences, as barcode or design principle, may fuel chemical evolution. Screening in appropriate test system may not only provide delivery candidates, but also a refined understanding of cellular delivery including novel, unpredictable mechanisms. Combined with rational design and computational algorithms, candidates can be further optimized in subsequent evolution cycles into nanocarriers with improved safety and efficacy. Optimization of nanocarriers differs for various cargos, as illustrated for plasmid DNA, siRNA, mRNA, proteins, or genome-editing nucleases.
Collapse
|
10
|
Richter F, Martin L, Leer K, Moek E, Hausig F, Brendel JC, Traeger A. Tuning of endosomal escape and gene expression by functional groups, molecular weight and transfection medium: a structure-activity relationship study. J Mater Chem B 2020; 8:5026-5041. [PMID: 32319993 DOI: 10.1039/d0tb00340a] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The use of genetic material by non-viral transfer systems is still in its initial stages, but there are high expectations for the development of targeted therapies. However, nucleic acids cannot enter cells without help, they must be well protected to prevent degradation and overcome a variety of biological barriers, the endosomal barrier being one of the greatest cellular challenges. Herein, the structure-property-relationship was investigated in detail, using well-defined polymers. Polyacrylamides were synthesized via RAFT polymerization resulting in a polymer library of (i) different cationic groups as aminoethyl acrylamide (AEAm), dimethylaminoethyl acrylamide (DMAEAm), dimethylaminopropyl acrylamide (DMAPAm) and guanidinopropyl acrylamide (GPAm); (ii) different degree of polymerization; and investigated (iii) in different cell culture settings. The influence of molar mass and cationic moiety on complex formation with pDNA, cytotoxicity and transfection efficiency of the polymers were investigated. The systematic approach identified a pH-independent guanidinium-containing homopolymer (PGPAm89) as the polymer with the highest transfection efficiency and superior endosomal release under optimal conditions. Since PGPAm89 is not further protonated inside endosomes, common escape theories appear unsuitable. Therefore, the interaction with bis(monoacryloylglycerol)phosphate, a lipid specific for endosomal vesicles, was investigated. Our research suggests that the interactions between amines and lipids may be more relevant than anticipated.
Collapse
Affiliation(s)
- Friederike Richter
- Laboratory of Organic and Macromolecular Chemistry (IOMC), Friedrich Schiller University Jena, Humboldtstrasse 10, 07743 Jena, Germany.
| | | | | | | | | | | | | |
Collapse
|
11
|
Xie X, Chen Y, Chen Z, Feng Y, Wang J, Li T, Li S, Qin X, Wu C, Zheng C, Zhu J, You F, Liu Y, Yang H. Polymeric Hybrid Nanomicelles for Cancer Theranostics: An Efficient and Precise Anticancer Strategy for the Codelivery of Doxorubicin/miR-34a and Magnetic Resonance Imaging. ACS APPLIED MATERIALS & INTERFACES 2019; 11:43865-43878. [PMID: 31684723 DOI: 10.1021/acsami.9b14908] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
To realize precise tumor therapy, a versatile oncotherapy nanoplatform integrating both diagnostic and therapeutic functions is necessary. Herein, we fabricated a hybrid micelle (HM) utilizing two amphiphilic diblock copolymers, polyethylenimine-polycaprolactone (PEI-PCL) and diethylenetriaminepentaacetic acid gadolinium(III) (Gd-DTPA)-conjugated polyethyleneglycol-polycaprolactone (Gd-PEG-PCL), to codeliver the small-molecule chemotherapy drugs doxorubicin (Dox) and microRNA-34a (miR-34a), denoted as Gd-HM-Dox/34a. Conjugating Gd-DTPA on the surface of hybrid micelles, leading the relaxation rate of Gd-DTPA increased more than 1.4 times (13.6 mM-1 S-1). Furthermore, hybrid micelles enhanced the ability of miR-34a to escape from lysosomes/endosomes and Dox release to the nucleus. In addition, the released miR-34a subsequently downregulates Bcl-2, cyclin D1, CDK6, and Bax expression and inhibits proliferation and migration of MDA-MB-231 breast cancer cells. Moreover, the suitable micelle size improved the penetration of Dox into three-dimensional (3D) multicellular spheroids compared with Gd-HM-Dox and Free Dox, generating efficient cell killing in the 3D multicellular spheroids. Furthermore, the Gd-HM-Dox/34a exhibited augmented accumulation in the tumor tissue, which improved the magnetic resonance (MR) imaging contrast of solid tumors and enhanced the combined efficiency of chemotherapeutic drugs Dox and therapeutic gene miR-34a in suppressing tumor growth on MDA-MB-231 tumor-bearing mice. Therefore, we established a hybrid micelle to offer a promising theranostic approach that inhibits tumor growth and enhances MR imaging.
Collapse
Affiliation(s)
- Xiaoxue Xie
- Department of Biophysics, School of Life Science and Technology , University of Electronic Science and Technology of China , Chengdu 610054 , Sichuan , P.R. China
| | - Yu Chen
- Department of Biophysics, School of Life Science and Technology , University of Electronic Science and Technology of China , Chengdu 610054 , Sichuan , P.R. China
| | - Zhongyuan Chen
- Department of Biophysics, School of Life Science and Technology , University of Electronic Science and Technology of China , Chengdu 610054 , Sichuan , P.R. China
| | - Yi Feng
- Department of Biophysics, School of Life Science and Technology , University of Electronic Science and Technology of China , Chengdu 610054 , Sichuan , P.R. China
| | - Jing Wang
- Department of Biophysics, School of Life Science and Technology , University of Electronic Science and Technology of China , Chengdu 610054 , Sichuan , P.R. China
| | - Tingting Li
- Department of Biophysics, School of Life Science and Technology , University of Electronic Science and Technology of China , Chengdu 610054 , Sichuan , P.R. China
| | - Shun Li
- Department of Biophysics, School of Life Science and Technology , University of Electronic Science and Technology of China , Chengdu 610054 , Sichuan , P.R. China
- Center for Information in Biology , University of Electronic Science and Technology of China , Chengdu 610054 , Sichuan , P.R. China
| | - Xiang Qin
- Department of Biophysics, School of Life Science and Technology , University of Electronic Science and Technology of China , Chengdu 610054 , Sichuan , P.R. China
- Center for Information in Biology , University of Electronic Science and Technology of China , Chengdu 610054 , Sichuan , P.R. China
| | - Chunhui Wu
- Department of Biophysics, School of Life Science and Technology , University of Electronic Science and Technology of China , Chengdu 610054 , Sichuan , P.R. China
- Center for Information in Biology , University of Electronic Science and Technology of China , Chengdu 610054 , Sichuan , P.R. China
| | - Chuan Zheng
- Hospital of Chengdu University of Traditional Chinese Medicine , No. 39 Shi-er-qiao Road , Chengdu 610072 , Sichuan , P.R. China
| | - Jie Zhu
- Hospital of Chengdu University of Traditional Chinese Medicine , No. 39 Shi-er-qiao Road , Chengdu 610072 , Sichuan , P.R. China
| | - Fengming You
- Hospital of Chengdu University of Traditional Chinese Medicine , No. 39 Shi-er-qiao Road , Chengdu 610072 , Sichuan , P.R. China
| | - Yiyao Liu
- Department of Biophysics, School of Life Science and Technology , University of Electronic Science and Technology of China , Chengdu 610054 , Sichuan , P.R. China
- Center for Information in Biology , University of Electronic Science and Technology of China , Chengdu 610054 , Sichuan , P.R. China
- Hospital of Chengdu University of Traditional Chinese Medicine , No. 39 Shi-er-qiao Road , Chengdu 610072 , Sichuan , P.R. China
| | - Hong Yang
- Department of Biophysics, School of Life Science and Technology , University of Electronic Science and Technology of China , Chengdu 610054 , Sichuan , P.R. China
- Center for Information in Biology , University of Electronic Science and Technology of China , Chengdu 610054 , Sichuan , P.R. China
| |
Collapse
|
12
|
Barrios-Gumiel A, Sánchez-Nieves J, Pedziwiatr-Werbicka E, Abashkin V, Shcharbina N, Shcharbin D, Glińska S, Ciepluch K, Kuc-Ciepluch D, Lach D, Bryszewska M, Gómez R, de la Mata FJ. Effect of PEGylation on the biological properties of cationic carbosilane dendronized gold nanoparticles. Int J Pharm 2019; 573:118867. [PMID: 31765788 DOI: 10.1016/j.ijpharm.2019.118867] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Revised: 11/06/2019] [Accepted: 11/11/2019] [Indexed: 12/26/2022]
Abstract
Heterofunctionalized gold nanoparticles (AuNPs) were obtained in a one pot reaction of gold precursor with cationic carbosilane dendrons (first to third generations, 1-3G) and (polyethylene)glycol (PEG) ligands in the presence of a reducing agent. The final dendron/PEG proportion on AuNPs depends on the initial dendron/PEG ratio (3/1, 1/1, 1/3) and dendron generation. AuNPs were characterized by transmission electron microscopy (TEM), dynamic light scattering (DLS), ultraviolet spectroscopy (UV-VIS), thermogravimetric analysis (TGA), nuclear magnetic resonance (1H NMR) and zeta potential (ZP). Several assays have been carried out to determine the relevance of PEG/dendron ratio and dendron generation in the biomedical properties of PEGylated AuNPs and the results have been compared with those obtained for non-PEGylated AuNPs. Finally, analyses of PEG recognition by anti-PEG antibodies were carried out. In general, haemolysis, platelet aggregation and toxicity were reduced after PEGylation of AuNPs, the effect being dependent on dendron generation and dendron/PEG ratio. Dendron generation determines the exposure of PEG ligand and the interaction of this ligand with AuNPs environment. On the other hand, increasing PEG proportion diminishes toxicity but also favors interaction with antibodies.
Collapse
Affiliation(s)
- Andrea Barrios-Gumiel
- Dpto. de Química Orgánica y Química Inorgánica, Universidad de Alcalá (UAH), Campus Universitario, E-28871 Alcalá de Henares, Madrid, Spain; Instituto de Investigación Química "Andrés M. del Río" (IQAR), Universidad de Alcalá (UAH), Spain; Networking Research Center for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain; Instituto Ramón y Cajal de Investigación Sanitaria, IRYCIS, Spain
| | - Javier Sánchez-Nieves
- Dpto. de Química Orgánica y Química Inorgánica, Universidad de Alcalá (UAH), Campus Universitario, E-28871 Alcalá de Henares, Madrid, Spain; Instituto de Investigación Química "Andrés M. del Río" (IQAR), Universidad de Alcalá (UAH), Spain; Networking Research Center for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain; Instituto Ramón y Cajal de Investigación Sanitaria, IRYCIS, Spain.
| | - Elzbieta Pedziwiatr-Werbicka
- University of Lodz, Faculty of Biology and Environmental Protection, Department of General Biophysics, 141/143 Pomorska Street, 90-236 Lodz, Poland.
| | - Viktar Abashkin
- Institute of Biophysics and Cell Engineering of NASB, Minsk, Belarus
| | - Natallia Shcharbina
- Clinical Unit "Eleous" at Religious Community «All Saints Parish in Minsk Eparchy of Belarusian Orthodox Church», Minsk, Belarus.
| | - Dzmitry Shcharbin
- Institute of Biophysics and Cell Engineering of NASB, Minsk, Belarus
| | - Sława Glińska
- University of Lodz, Faculty of Biology and Environmental Protection, Laboratory of Microscopic Imaging and Specialized Biological Techniques, Banacha 12/16, 90-237 Lodz, Poland.
| | - Karol Ciepluch
- Department of Biochemistry and Genetics, Jan Kochanowski Universit, Świętokrzyska Street 15, 25-406 Kielce, Poland
| | - Dorota Kuc-Ciepluch
- Department of Biochemistry and Genetics, Jan Kochanowski Universit, Świętokrzyska Street 15, 25-406 Kielce, Poland
| | - Dominika Lach
- University of Lodz, Faculty of Biology and Environmental Protection, Department of General Biophysics, 141/143 Pomorska Street, 90-236 Lodz, Poland
| | - Maria Bryszewska
- University of Lodz, Faculty of Biology and Environmental Protection, Department of General Biophysics, 141/143 Pomorska Street, 90-236 Lodz, Poland
| | - Rafael Gómez
- Dpto. de Química Orgánica y Química Inorgánica, Universidad de Alcalá (UAH), Campus Universitario, E-28871 Alcalá de Henares, Madrid, Spain; Instituto de Investigación Química "Andrés M. del Río" (IQAR), Universidad de Alcalá (UAH), Spain; Networking Research Center for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain; Instituto Ramón y Cajal de Investigación Sanitaria, IRYCIS, Spain.
| | - F Javier de la Mata
- Dpto. de Química Orgánica y Química Inorgánica, Universidad de Alcalá (UAH), Campus Universitario, E-28871 Alcalá de Henares, Madrid, Spain; Instituto de Investigación Química "Andrés M. del Río" (IQAR), Universidad de Alcalá (UAH), Spain; Networking Research Center for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain; Instituto Ramón y Cajal de Investigación Sanitaria, IRYCIS, Spain.
| |
Collapse
|
13
|
Strategies in the design of endosomolytic agents for facilitating endosomal escape in nanoparticles. Biochimie 2019; 160:61-75. [DOI: 10.1016/j.biochi.2019.02.012] [Citation(s) in RCA: 58] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Accepted: 02/19/2019] [Indexed: 12/23/2022]
|
14
|
Cha S, Lee SH, Kang SH, Hasan MN, Kim YJ, Cho S, Lee YK. Antibody-mediated oral delivery of therapeutic DNA for type 2 diabetes mellitus. Biomater Res 2018; 22:19. [PMID: 30065848 PMCID: PMC6062860 DOI: 10.1186/s40824-018-0129-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2018] [Accepted: 06/27/2018] [Indexed: 12/02/2022] Open
Abstract
Background Diabetes mellitus (DM) is a chronic progressive metabolic disease that involves uncontrolled elevation of blood glucose levels. Among various therapeutic approaches, GLP-1 prevents type 2 diabetes mellitus (T2DM) patients from experiencing hyperglycemic episodes. However, the short half-life (< 5 min) and rapid clearance of GLP-1 often limits its therapeutic use. Here, we developed an oral GLP-1 gene delivery system to achieve an extended antidiabetic effect. Methods Human IgG1 (hIgG1)-Fc-Arg/pDNA complexes were prepared by an electrostatic complexation of the expression plasmid with various ratios of the positively modified Fc fragments of an antibody (hIgG1-Fc-Arg) having a targeting ability to FcRn receptor. The shape and size of the complexes were examined by atomic force and field emission electron microscope. The stability of the complexes was tested in simulated gastrointestinal pH and physiological serum condition. Cellular uptake, transport, and toxicity of the complexes were tested in the Caco-2 cells. Biodistribution and antidiabetic effect of the complexes were observed in either Balb/c mice or Lepdb/db mice. Results A 50/1 ratio of the hIgG1-Fc-Arg/pDNA produced a complex structure having approximately 40 ~ 60 nm size and also demonstrated protection of pDNA in the complex from the physiological pH and serum conditions. Cellular uptake and transport of the complex were demonstrated in Caco-2 cells having FcRn receptor expression and forming the monolayer-polarized structure. The cellular toxicity of both delivery vehicle and the complex revealed their minimal toxicity comparable with nontoxicity of a commercial transfection reagent. Biodistribution of the complex showed the detectable distribution of the complex in the most parts of gastrointestinal tract due to ubiquitous expression of the FcRn receptors. An in vivo type 2 diabetes treatment study of oral administration of hIgG1-Fc-9Arg/pGLP-1 complexes showed absorption and expression in GI tract of either Balb/c mice or Lepdb/db mice. Conclusion In this study, we developed an oral GLP-1 gene delivery system on the platform of cationic hIgG1-Fc-9Arg. Prolonged t1/2, less immunoactivity, and better bioactivities of hIgG-Fc-9Arg/pGLP-1 complexes appeared to be a promising approach to achieve potent treatment of type 2 diabetes treatment. Electronic supplementary material The online version of this article (10.1186/s40824-018-0129-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Seungbin Cha
- 1Department of Biomedical Chemistry, Konkuk University, Chungju, 27478 Republic of Korea
| | | | | | - Mohammad Nazmul Hasan
- 3Department of Chemical and Biological Engineering, Korea National University of Transportation, Chungju, 27469 Republic of Korea
| | - Young Jun Kim
- 1Department of Biomedical Chemistry, Konkuk University, Chungju, 27478 Republic of Korea
| | - Sungpil Cho
- 44D Biomaterials Center, Korea National University of Transportation, Jeungpyeong, 27909 Republic of Korea
| | - Yong-Kyu Lee
- KB-Biomed, Chungju, 27469 Republic of Korea.,3Department of Chemical and Biological Engineering, Korea National University of Transportation, Chungju, 27469 Republic of Korea.,44D Biomaterials Center, Korea National University of Transportation, Jeungpyeong, 27909 Republic of Korea
| |
Collapse
|
15
|
Krhac Levacic A, Morys S, Wagner E. Solid-phase supported design of carriers for therapeutic nucleic acid delivery. Biosci Rep 2017; 37:BSR20160617. [PMID: 28963371 PMCID: PMC5662914 DOI: 10.1042/bsr20160617] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Revised: 09/26/2017] [Accepted: 09/27/2017] [Indexed: 12/21/2022] Open
Abstract
Nucleic acid molecules are important therapeutic agents in the field of antisense oligonucleotide, RNA interference, and gene therapies. Since nucleic acids are not able to cross cell membranes and enter efficiently into cells on their own, the development of efficient, safe, and precise delivery systems is the crucial challenge for development of nucleic acid therapeutics. For the delivery of nucleic acids to their intracellular site of action, either the cytosol or the nucleus, several extracellular and intracellular barriers have to be overcome. Multifunctional carriers may handle the different special requirements of each barrier. The complexity of such macromolecules however poses a new hurdle in medical translation, which is the chemical production in reproducible and well-defined form. Solid-phase assisted synthesis (SPS) presents a solution for this challenge. The current review provides an overview on the design and SPS of precise sequence-defined synthetic carriers for nucleic acid cargos.
Collapse
Affiliation(s)
- Ana Krhac Levacic
- Pharmaceutical Biotechnology, Center for System-Based Drug Research, and Center for NanoScience (CeNS), Ludwig-Maximilians-Universität München, Butenandtstrasse 5-13, D-81377 Munich, Germany
| | - Stephan Morys
- Pharmaceutical Biotechnology, Center for System-Based Drug Research, and Center for NanoScience (CeNS), Ludwig-Maximilians-Universität München, Butenandtstrasse 5-13, D-81377 Munich, Germany
| | - Ernst Wagner
- Pharmaceutical Biotechnology, Center for System-Based Drug Research, and Center for NanoScience (CeNS), Ludwig-Maximilians-Universität München, Butenandtstrasse 5-13, D-81377 Munich, Germany
- Nanosystems Initiative Munich, Schellingstrasse 4, D-80799 Munich, Germany
| |
Collapse
|
16
|
Lee JJ, Saiful Yazan L, Che Abdullah CA. A review on current nanomaterials and their drug conjugate for targeted breast cancer treatment. Int J Nanomedicine 2017; 12:2373-2384. [PMID: 28392694 PMCID: PMC5376210 DOI: 10.2147/ijn.s127329] [Citation(s) in RCA: 63] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Breast cancer is the most common malignancy worldwide, especially among women, with substantial after-treatment effects. The survival rates of breast cancer have decreased over the years even with the existence of various therapeutic strategies, specifically, chemotherapy. Clinical drugs administered for breast cancer appear to be non-targeting to specific cancer sites leading to severe side effects and potentially harming healthy cells instead of just killing cancer cells. This leads to the need for designing a targeted drug delivery system. Nanomaterials, both organic and inorganic, are potential drug nanocarriers with the ability of targeting, imaging and tracking. Various types of nanomaterials have been actively researched together with their drug conjugate. In this review, we focus on selected nanomaterials, namely solid-lipid, liposomal, polymeric, magnetic nanoparticles, quantum dots, and carbon nanotubes and their drug conjugates, for breast cancer studies. Their advantages, disadvantages and previously conducted studies were highlighted.
Collapse
|
17
|
Takeda KM, Yamasaki Y, Dirisala A, Ikeda S, Tockary TA, Toh K, Osada K, Kataoka K. Effect of shear stress on structure and function of polyplex micelles from poly(ethylene glycol)-poly(l-lysine) block copolymers as systemic gene delivery carrier. Biomaterials 2017; 126:31-38. [PMID: 28254691 DOI: 10.1016/j.biomaterials.2017.02.012] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Revised: 02/09/2017] [Accepted: 02/10/2017] [Indexed: 01/26/2023]
Abstract
Structural stability of polyplex micelles (PMs), prepared from plasmid DNA (pDNA) and poly(ethylene glycol)-b-poly(l-lysine) block catiomer (PEG-PLys), was evaluated in terms of their resistance against shear stress. When exposed to shear stress at magnitudes typically present in the blood stream, structural deterioration was observed in PMs owing to the partial removal of PEG-PLys strands. Eventually, impaired PEG coverage of the polyplex core led to accelerated degradation by nucleases, implying that structural deterioration by shear stress in blood stream may be a major cause of rapid clearance of PMs from blood circulation. To address this issue, introduction of disulfide crosslinking into the PM core was shown to be an efficient strategy, which successfully mitigated unfavorable effects of shear stress. Furthermore, improved in vivo blood retention profile and subsequently enhanced antitumor efficacy in systemic treatment of pancreatic adenocarcinoma were confirmed for the crosslinked PMs loaded with pDNA encoding an anti-angiogenic protein, suggesting that high stability under the shear stress during blood circulation may be a critical factor in systemically applicable gene delivery systems.
Collapse
Affiliation(s)
- Kaori M Takeda
- Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan
| | - Yuichi Yamasaki
- Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan; Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan.
| | - Anjaneyulu Dirisala
- Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan; Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan; Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan
| | - Sorato Ikeda
- Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan
| | - Theofilus A Tockary
- Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan; Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan
| | - Kazuko Toh
- Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan
| | - Kensuke Osada
- Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan; Japan Science and Technology Agency, PRESTO, 4-1-8 Honcho, Kawaguchi, Saitama, 332-0012, Japan; Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan.
| | - Kazunori Kataoka
- Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan; Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan; Division of Clinical Biotechnology, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan; Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan.
| |
Collapse
|
18
|
Dube B, Pandey A, Joshi G, Sawant K. Hydrophobically modified polyethylenimine-based ternary complexes for targeting brain tumor: stability, in vitro and in vivo studies. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2017; 45:1685-1698. [PMID: 28278583 DOI: 10.1080/21691401.2017.1282497] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Hydrophobic modification of low molecular weight polyethylenimine (PEI 2 kDa) by cholic acid (ChA) was done to obtain PEI2-ChA. The nanoplexes of PEI2-ChA with gWIZ-GFP demonstrated increase transfection efficiency (∼27%) in NT8e cell lines. The cell-cycle analysis of NT8e cells (p53 mutant) treated with transferrin containing nanoplexes showed increased apoptosis of cells. In vitro protein expression revealed expression of exogenous p53 protein. In vivo imaging of mice showed localized signal for GFP protein in brain region. The tumors of mice treated with transferrin containing nanoplexes of PEI2-ChA were ∼5 times smaller in size than the tumor of untreated animals.
Collapse
Affiliation(s)
- Brahmanand Dube
- a Pharmacy Department, Faculty of Pharmacy , The M.S. University of Baroda , Kalabhavan, Vadodara , India
| | - Abhijeet Pandey
- a Pharmacy Department, Faculty of Pharmacy , The M.S. University of Baroda , Kalabhavan, Vadodara , India
| | - Ganesh Joshi
- b Genetic Engineering Lab , ACTREC Tata Memorial Centre , Kharghar, Navi Mumbai , India
| | - Krutika Sawant
- a Pharmacy Department, Faculty of Pharmacy , The M.S. University of Baroda , Kalabhavan, Vadodara , India
| |
Collapse
|
19
|
Deller RC, Diamanti P, Morrison G, Reilly J, Ede BC, Richardson R, Le Vay K, Collins AM, Blair A, Perriman AW. Functionalized Triblock Copolymer Vectors for the Treatment of Acute Lymphoblastic Leukemia. Mol Pharm 2017; 14:722-732. [DOI: 10.1021/acs.molpharmaceut.6b01008] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Robert C. Deller
- School
of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TH, United Kingdom
| | - Paraskevi Diamanti
- School
of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TH, United Kingdom
- Bristol
Institute for Transfusion Sciences, NHS Blood and Transplant, Bristol BS34 7QH, United Kingdom
| | - Gabriella Morrison
- School
of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TH, United Kingdom
| | - James Reilly
- School
of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TH, United Kingdom
| | - Benjamin C. Ede
- School
of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TH, United Kingdom
| | - Robert Richardson
- School
of Physics, University of Bristol, Bristol BS8 1TH, United Kingdom
| | - Kristian Le Vay
- School
of Biochemistry, University of Bristol, Bristol BS8 1TH, United Kingdom
- Bristol
Centre for Functional Nanomaterials, University of Bristol, Bristol BS8 1TH, United Kingdom
| | - Andrew M. Collins
- School
of Physics, University of Bristol, Bristol BS8 1TH, United Kingdom
- Bristol
Centre for Functional Nanomaterials, University of Bristol, Bristol BS8 1TH, United Kingdom
| | - Allison Blair
- School
of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TH, United Kingdom
- Bristol
Institute for Transfusion Sciences, NHS Blood and Transplant, Bristol BS34 7QH, United Kingdom
| | - Adam W. Perriman
- School
of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TH, United Kingdom
| |
Collapse
|
20
|
Miao L, Liu Q, Lin CM, Luo C, Wang Y, Liu L, Yin W, Hu S, Kim WY, Huang L. Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors. Cancer Res 2016; 77:719-731. [PMID: 27864344 DOI: 10.1158/0008-5472.can-16-0866] [Citation(s) in RCA: 151] [Impact Index Per Article: 18.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2016] [Revised: 09/26/2016] [Accepted: 10/21/2016] [Indexed: 01/12/2023]
Abstract
The off-target distribution of anticancer nanoparticles to fibroblasts creates a barrier to the effective treatment of desmoplastic tumors. However, we hypothesized that this nanoparticle detriment might be exploited to target the expression of secreted cytotoxic proteins from tumor-associated fibroblasts (TAF) as an anticancer strategy. In addressing this hypothesis, plasmids encoding the secretable TNF-related factor sTRAIL were loaded into lipid-coated protamine DNA complexes and administered by infusion in a murine xenograft model of human desmoplastic bladder carcinoma. Three doses were sufficient to generate approximately 70% of TAFs as sTRAIL-producing cells. sTRAIL triggered apoptosis in tumor cell nests adjacent to TAFs. Furthermore, it reverted residual fibroblasts to a quiescent state due to insufficient activation, further compromising tumor growth and remodeling the microenvironment to favor second-wave nanotherapy. We confirmed the efficacy of this strategy in an orthotopic xenograft model of human pancreatic cancer, where the desmoplastic stroma is well known to be a major barrier to the delivery of therapeutic nanoparticles. Collectively, our results offer a proof of concept for the use of nanoparticles to modify TAFs as an effective strategy to treat desmoplastic cancers. Cancer Res; 77(3); 719-31. ©2016 AACR.
Collapse
Affiliation(s)
- Lei Miao
- Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Qi Liu
- Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.,UNC & NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - C Michael Lin
- Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Cong Luo
- Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.,Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | - Yuhua Wang
- Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Lina Liu
- Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Weiyan Yin
- UNC & NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Shihao Hu
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing, China
| | - William Y Kim
- Department of Medicine, Division of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Leaf Huang
- Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. .,UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| |
Collapse
|
21
|
Abstract
Research in the field of nonviral gene delivery is in the initial stages relative to the more commonly known viral systems. However, nonviral systems may, in the near future overcome some of the problems inherent to currently employed viral gene delivery systems. These problems range from limited payload capacity and general production issues to immune and toxic reactions, as well as the potential for catastrophic viral recombination. Self-assembling complexes of nucleic acids and synthetic polymers, commonly referred to as `polyplexes', are formed as the result of electrostatic interactions between the negatively charged phosphate groups of the DNA and the positively charged groups of the polycation. A wide array of polycations are available for such studies, including those with linear, branched, dendritic and block or graft copolymer architectures. These polycations vary greatly in chemical composition as well as the number of repeating units, providing for a wide range of different polyplexes that can be easily assembled. Some of the current gene delivery systems are described which serve as potential reagents in the field of polymer-based gene delivery.
Collapse
Affiliation(s)
- Catherine L. Gebhart
- Department of Pharmaceutical Sciences College of Pharmacy University of Nebraska Medical Center 986025, Nebraska Medical Center Omaha, NE 68198-6025, USA
| | - Alexander V. Kabanov
- Department of Pharmaceutical Sciences College of Pharmacy University of Nebraska Medical Center 986025, Nebraska Medical Center Omaha, NE 68198-6025, USA
| |
Collapse
|
22
|
Zhang W, Müller K, Kessel E, Reinhard S, He D, Klein PM, Höhn M, Rödl W, Kempter S, Wagner E. Targeted siRNA Delivery Using a Lipo-Oligoaminoamide Nanocore with an Influenza Peptide and Transferrin Shell. Adv Healthc Mater 2016; 5:1493-504. [PMID: 27109317 DOI: 10.1002/adhm.201600057] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Revised: 02/23/2016] [Indexed: 01/06/2023]
Abstract
Developing RNA-interference-based therapeutic approaches with efficient and targeted cytosolic delivery of small interfering RNA (siRNA) is remaining a critical challenge since two decades. Herein, a multifunctional transferrin receptor (TfR)-targeted siRNA delivery system (Tf&INF7) is designed based on siRNA complexes formed with the cationic lipo-oligoamino amide 454, sequentially surface-modified with polyethylene glycol-linked transferrin (Tf) for receptor targeting and the endosomolytic peptide INF7 for efficient cytosolic release of the siRNA. Effective Tf&INF7 polyplex internalization and target gene silencing are demonstrated for the TfR overexpressing tumor cell lines (K562, D145, and N2a). Treatment with antitumoral EG5 siRNA results in a block of tumor cell growth and triggered apoptosis. Tf-modified polyplexes are far more effective than the corresponding albumin- (Alb) or nonmodified 454 polyplexes. Competition experiments with excess of Tf demonstrate TfR target specificity. As alternative to the ligand Tf, an anti-murine TfR antibody is incorporated into the polyplexes for specific targeting and gene silencing in the murine N2a cell line. In vivo distribution studies not only demonstrate an enhanced tumor residence of siRNA in N2a tumor-bearing mice with the Tf&INF7 as compared to the 454 polyplex group but also a reduced siRNA nanoparticle stability limiting the in vivo performance.
Collapse
Affiliation(s)
- Wei Zhang
- Pharmaceutical Biotechnology Department of Pharmacy Ludwig‐Maximilians‐Universität München (LMU) Butenandtstrasse 5‐13 D‐81377 Munich Germany
| | - Katharina Müller
- Pharmaceutical Biotechnology Department of Pharmacy Ludwig‐Maximilians‐Universität München (LMU) Butenandtstrasse 5‐13 D‐81377 Munich Germany
| | - Eva Kessel
- Pharmaceutical Biotechnology Department of Pharmacy Ludwig‐Maximilians‐Universität München (LMU) Butenandtstrasse 5‐13 D‐81377 Munich Germany
- Nanosystems Initiative Munich Schellingstrasse 4 D‐80799 Munich Germany
| | - Sören Reinhard
- Pharmaceutical Biotechnology Department of Pharmacy Ludwig‐Maximilians‐Universität München (LMU) Butenandtstrasse 5‐13 D‐81377 Munich Germany
| | - Dongsheng He
- Pharmaceutical Biotechnology Department of Pharmacy Ludwig‐Maximilians‐Universität München (LMU) Butenandtstrasse 5‐13 D‐81377 Munich Germany
- Nanosystems Initiative Munich Schellingstrasse 4 D‐80799 Munich Germany
| | - Philipp M. Klein
- Pharmaceutical Biotechnology Department of Pharmacy Ludwig‐Maximilians‐Universität München (LMU) Butenandtstrasse 5‐13 D‐81377 Munich Germany
| | - Miriam Höhn
- Pharmaceutical Biotechnology Department of Pharmacy Ludwig‐Maximilians‐Universität München (LMU) Butenandtstrasse 5‐13 D‐81377 Munich Germany
| | - Wolfgang Rödl
- Pharmaceutical Biotechnology Department of Pharmacy Ludwig‐Maximilians‐Universität München (LMU) Butenandtstrasse 5‐13 D‐81377 Munich Germany
| | - Susanne Kempter
- Department of Physics Ludwig‐Maximilians‐Universität München Geschwister‐Scholl‐Platz 1 80539 Munich Germany
| | - Ernst Wagner
- Pharmaceutical Biotechnology Department of Pharmacy Ludwig‐Maximilians‐Universität München (LMU) Butenandtstrasse 5‐13 D‐81377 Munich Germany
- Nanosystems Initiative Munich Schellingstrasse 4 D‐80799 Munich Germany
| |
Collapse
|
23
|
Nam JP, Nah JW. Target gene delivery from targeting ligand conjugated chitosan–PEI copolymer for cancer therapy. Carbohydr Polym 2016; 135:153-61. [DOI: 10.1016/j.carbpol.2015.08.053] [Citation(s) in RCA: 64] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2015] [Revised: 08/17/2015] [Accepted: 08/18/2015] [Indexed: 01/01/2023]
|
24
|
Kang H, Mintri S, Menon AV, Lee HY, Choi HS, Kim J. Pharmacokinetics, pharmacodynamics and toxicology of theranostic nanoparticles. NANOSCALE 2015; 7:18848-62. [PMID: 26528835 PMCID: PMC4648690 DOI: 10.1039/c5nr05264e] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
Nanoparticles (NPs) are considered a promising tool in both diagnosis and therapeutics. Theranostic NPs possess the combined properties of targeted imaging and drug delivery within a single entity. While the categorization of theranostic NPs is based on their structure and composition, the pharmacokinetics of NPs are significantly influenced by the physicochemical properties of theranostic NPs as well as the routes of administration. Consequently, altered pharmacokinetics modify the pharmacodynamic efficacy and toxicity of NPs. Although theranostic NPs hold great promise in nanomedicine and biomedical applications, a lack of understanding persists on the mechanisms of the biodistribution and adverse effects of NPs. To better understand the diagnostic and therapeutic functions of NPs, this review discusses the factors that influence the pharmacokinetics, pharmacodynamics and toxicology of theranostic NPs, along with several strategies for developing novel diagnostic and therapeutic modalities.
Collapse
Affiliation(s)
- Homan Kang
- Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA. Phone: 617-667-6024, Fax: 617-667-0214
| | - Shrutika Mintri
- Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA. Phone: 617-373-3214, Fax: 617-373-8886
| | - Archita Venugopal Menon
- Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA. Phone: 617-373-3214, Fax: 617-373-8886
| | - Hea Yeon Lee
- Department of Nanotechnology, Detroit R&D, Inc., Detroit, MI 48201, USA
| | - Hak Soo Choi
- Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA. Phone: 617-667-6024, Fax: 617-667-0214
| | - Jonghan Kim
- Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA. Phone: 617-373-3214, Fax: 617-373-8886
| |
Collapse
|
25
|
Schulz JD, Gauthier MA, Leroux JC. Improving oral drug bioavailability with polycations? Eur J Pharm Biopharm 2015; 97:427-37. [DOI: 10.1016/j.ejpb.2015.04.025] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2015] [Revised: 03/30/2015] [Accepted: 04/22/2015] [Indexed: 11/24/2022]
|
26
|
Zhang W, Rödl W, He D, Döblinger M, Lächelt U, Wagner E. Combination of sequence-defined oligoaminoamides with transferrin-polycation conjugates for receptor-targeted gene delivery. J Gene Med 2015; 17:161-72. [DOI: 10.1002/jgm.2838] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2015] [Revised: 07/22/2015] [Accepted: 07/29/2015] [Indexed: 11/06/2022] Open
Affiliation(s)
- Wei Zhang
- Pharmaceutical Biotechnology, Centre for System-Based Drug Research; Ludwig-Maximilians-Universität Munich; Munich Germany
| | - Wolfgang Rödl
- Pharmaceutical Biotechnology, Centre for System-Based Drug Research; Ludwig-Maximilians-Universität Munich; Munich Germany
| | - Dongsheng He
- Pharmaceutical Biotechnology, Centre for System-Based Drug Research; Ludwig-Maximilians-Universität Munich; Munich Germany
- Nanosystems Initiative Munich; Munich Germany
| | - Markus Döblinger
- Department of Chemistry; Ludwig-Maximilians-Universität Munich; Munich Germany
| | - Ulrich Lächelt
- Pharmaceutical Biotechnology, Centre for System-Based Drug Research; Ludwig-Maximilians-Universität Munich; Munich Germany
- Nanosystems Initiative Munich; Munich Germany
| | - Ernst Wagner
- Pharmaceutical Biotechnology, Centre for System-Based Drug Research; Ludwig-Maximilians-Universität Munich; Munich Germany
- Nanosystems Initiative Munich; Munich Germany
| |
Collapse
|
27
|
Tian S, Cao D, Zou H, Bai F, Wang Z, Pan S, Feng M. Endothelial cell-targeted pVEGF165 polyplex plays a pivotal role in inhibiting intimal thickening after vascular injury. Int J Nanomedicine 2015; 10:5751-68. [PMID: 26425083 PMCID: PMC4583553 DOI: 10.2147/ijn.s88109] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Upregulation of vascular endothelial growth factor (VEGF) expression can inhibit intimal thickening after vascular injury. However, the lack of efficient gene delivery systems leads to insufficient VEGF expression, which prevents its application in gene therapy. In the present study, to improve the delivery of the plasmid vector with the VEGF gene (pVEGF165) to the injured vessel wall, we explored the potentially important difference between endothelial cell-targeted and nontargeted polymeric carriers. The αvβ3 integrin is overexpressed on activated endothelial cells but not on normal quiescent vessels. In this study, CDG2-cRGD, synthesized by conjugating an αvβ3 integrin-binding cyclic arginylglycylaspartic acid (cRGD) peptide with the Generation 2 polycation polyamidoamine (PAMAMG2)-g-cyclodextrin (termed as CDG2), was developed as a targetable carrier. It was observed that the specific integrin-ligand interactions greatly enhanced cellular internalization of CDG2-cRGD in human umbilical vein endothelial cells (HUVECs), which are notoriously difficult to transfect. Consequently, HUVECs were found to show remarkably high levels of VEGF165 expression induced by the CDG2-cRGD polyplex. Interestingly, VEGF165 overexpression in vivo was more complex than that in vitro, and in vivo assays demonstrated that the stimulus response to balloon injury in arteries could obviously upregulate VEGF165 expression in the saline-treated group, although it was not enough to prevent intimal thickening. In gene-transfected groups, intravascular delivery of pVEGF165 with the CDG2-cRGD polyplex into rabbits after vascular injury resulted in a significant inhibition of intimal thickening at 4 weeks, whereas the low therapeutic efficacy in the nontargeted CDG2-treated group was only comparable to that in the saline-treated group. It is becoming clear that the conflicting results of VEGF165 gene therapy in two gene-transfected groups are reflective of the pivotal role of the cRGD-conjugated carriers in achieving the beneficial therapeutic effects of vascular gene therapy.
Collapse
Affiliation(s)
- Shouqin Tian
- School of Pharmaceutical Sciences, Department of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China
| | - Duanwen Cao
- Department of Pharmaceutical Sciences, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China
| | - Haijuan Zou
- School of Pharmaceutical Sciences, Department of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China
| | - Feng Bai
- School of Pharmaceutical Sciences, Department of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China
| | - Zhongjuan Wang
- School of Pharmaceutical Sciences, Department of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China
| | - Shirong Pan
- School of Pharmaceutical Sciences, Department of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China ; Key Laboratory on Assisted Circulation, Ministry of Health, Guangzhou, People's Republic of China
| | - Min Feng
- School of Pharmaceutical Sciences, Department of Pharmacy, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China
| |
Collapse
|
28
|
Cheang TY, Xing ZH, Li ZL, Zhou HY, Wei JH, Zhou X, Xu AW, Lin Y, Wang SM. Delivery of AIB1 siRNA by Ca 2+/PEI/heparin composite nanoparticles effectively inhibits the growth of human breast cancer. J Mater Chem B 2015; 3:7623-7630. [PMID: 32262646 DOI: 10.1039/c5tb01490e] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Here, a novel carrier fabricated by the interaction of negatively charged heparin and positively charged PEI and Ca2+ was investigated to deliver AIB1 siRNA into breast cancer cells both in vitro and in vivo. Ca2+/PEI/heparin nanoparticles were prepared by simply mixing heparin, PEI and CaCl2 aqueous solution. Heparin in the Ca2+/PEI/heparin nanoparticles (40.9% heparin, w/w) decreased the cytotoxicity of PEI. According to the MTT assay, Ca2+/PEI/heparin NPs are superior to commercial Lipofectamine 2000 considering the safety. The Ca2+/PEI/heparin NPs are able to deliver siAIB1 into breast cancer cells as effectively as Lipofectamine 2000 both in vitro and in vivo. The in vivo experiment also indicated that the NF-κB/BCL-2 signal pathway might be the downstream signal pathway of AIB1 in regulating breast cancer proliferation and progression.
Collapse
Affiliation(s)
- T Y Cheang
- Department of Breast Surgery, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China.
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Zhan B, Shi K, Dong Z, Lv W, Zhao S, Han X, Wang H, Liu H. Coarse-Grained Simulation of Polycation/DNA-Like Complexes: Role of Neutral Block. Mol Pharm 2015; 12:2834-44. [PMID: 26076229 DOI: 10.1021/mp500861c] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Complexes formed by polycations and DNA are of great research interest because of their prospective application in gene therapy. Whereas the applications of multiblock based polycation generally exhibit promising features, a thorough understanding on the effect of neutral block incorporated in polycation is still lacking. By using coarse-grained dynamics simulation with the help of a simple model for solvent mediated interaction, we perform a theoretical study on the physicochemical properties of various polyplexes composed of a single DNA-like polyanion chain and numbers of linear polycationic chains with different modifications. By analyzing various properties, we find the hydrophobic/hydrophilic modifications of linear polycations may bring an improvement on one aspect of the properties as gene carrier but also involve a trade-off with another one. In particular, polycation with a hydrophobic middle block and a hydrophilic tail block display distinct advantages among di- and triblock linear polycations as gene carrier, while careful design of the hydrophobic block should be made to reduce the zeta potential. The simulation results are compared with available experimental data displaying good agreements.
Collapse
Affiliation(s)
- Bicai Zhan
- †State Key Laboratory of Chemical Engineering, ‡Department of Chemistry, and §State Environmental Protection Key Laboratory of Environmental Risk Assessment and Control on Chemical Process, East China University of Science and Technology, Shanghai 200237, China
| | - Kaihang Shi
- †State Key Laboratory of Chemical Engineering, ‡Department of Chemistry, and §State Environmental Protection Key Laboratory of Environmental Risk Assessment and Control on Chemical Process, East China University of Science and Technology, Shanghai 200237, China
| | - Zhexi Dong
- †State Key Laboratory of Chemical Engineering, ‡Department of Chemistry, and §State Environmental Protection Key Laboratory of Environmental Risk Assessment and Control on Chemical Process, East China University of Science and Technology, Shanghai 200237, China
| | | | - Shuangliang Zhao
- †State Key Laboratory of Chemical Engineering, ‡Department of Chemistry, and §State Environmental Protection Key Laboratory of Environmental Risk Assessment and Control on Chemical Process, East China University of Science and Technology, Shanghai 200237, China
| | | | | | - Honglai Liu
- †State Key Laboratory of Chemical Engineering, ‡Department of Chemistry, and §State Environmental Protection Key Laboratory of Environmental Risk Assessment and Control on Chemical Process, East China University of Science and Technology, Shanghai 200237, China
| |
Collapse
|
30
|
|
31
|
Hendricks WPD, Yang J, Sur S, Zhou S. Formulating the magic bullet: barriers to clinical translation of nanoparticle cancer gene therapy. Nanomedicine (Lond) 2015; 9:1121-4. [PMID: 25118704 DOI: 10.2217/nnm.14.63] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
|
32
|
Lächelt U, Wagner E. Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond). Chem Rev 2015; 115:11043-78. [DOI: 10.1021/cr5006793] [Citation(s) in RCA: 418] [Impact Index Per Article: 46.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Ulrich Lächelt
- Pharmaceutical
Biotechnology, Department of Pharmacy, Ludwig Maximilians Universität, 81377 Munich, Germany
- Nanosystems
Initiative
Munich (NIM), 80799 Munich, Germany
| | - Ernst Wagner
- Pharmaceutical
Biotechnology, Department of Pharmacy, Ludwig Maximilians Universität, 81377 Munich, Germany
- Nanosystems
Initiative
Munich (NIM), 80799 Munich, Germany
| |
Collapse
|
33
|
Liposome–protein corona in a physiological environment: Challenges and opportunities for targeted delivery of nanomedicines. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2015; 11:543-57. [DOI: 10.1016/j.nano.2014.11.003] [Citation(s) in RCA: 174] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2014] [Revised: 11/04/2014] [Accepted: 11/16/2014] [Indexed: 11/22/2022]
|
34
|
Navarro G, Sawant RR, Essex S, Tros de Ilarduya C, Torchilin VP. Phospholipid-polyethylenimine conjugate-based micelle-like nanoparticles for siRNA delivery. Drug Deliv Transl Res 2015; 1:25-33. [PMID: 22916337 DOI: 10.1007/s13346-010-0004-0] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Gene silencing using small interfering RNA (siRNA) is a promising therapeutic strategy for the treatment of various diseases, in particular, cancer. Recently, our group reported on a novel gene carrier, the micelle-like nanoparticle (MNP), based on the combination of a covalent conjugate of phospholipid and polyethylenimine (PLPEI) with polyethylene glycol (PEG) and lipids. These long-circulating MNPs loaded with plasmid DNA-mediated gene expression in distal tumors after systemic administration in vivo. In the current study, we investigated the potential of MNPs for siRNA delivery. MNPs were prepared by condensing siRNA with PLPEI at a nitrogen/phosphate ratio of 10, where the binding of siRNA is complete. The addition of a PEG/lipid coating to the PLPEI complexes generated particles with sizes of ca. 200 nm and a neutral surface charge compared with positively charged PLPEI polyplexes without the additional coating. MNPs protected the loaded siRNA against enzymatic digestion and enhanced the cellular uptake of the siRNA payload. MNPs carrying green fluorescent protein (GFP)-targeted siRNA effectively downregulated the gene in cells that stably express GFP. Finally, MNPs were non-toxic at a wide range of concentrations and for different cell lines.
Collapse
Affiliation(s)
- Gemma Navarro
- Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, 360 Huntington Ave, Boston, MA 02115, USA
| | | | | | | | | |
Collapse
|
35
|
Ballarín-González B, Thomsen TB, Howard KA. Clinical translation of RNAi-based treatments for respiratory diseases. Drug Deliv Transl Res 2015; 3:84-99. [PMID: 25787868 PMCID: PMC7097609 DOI: 10.1007/s13346-012-0098-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The ability to harness the RNA interference (RNAi) mechanism as a potential potent therapeutic has attracted great interest from academia and industry. Numerous preclinical and recent clinical trials have demonstrated the effectiveness of RNAi triggers such as synthetic small interfering RNA (siRNA). Chemical modification and delivery technologies can be utilized to avoid immune stimulation and improve the bioactivity and pharmacokinetics. Local application to the respiratory epithelia allows direct access to the site of respiratory pathogens that include influenza and respiratory syncytial virus (RSV). This review outlines the essential steps required for the clinical translation of RNAi-based respiratory therapies including disease and RNA target selection, siRNA design, respiratory barriers, and delivery solutions. Attention is given to antiviral therapies and preclinical evaluation with focus on the current status of anti-RSV clinical trials.
Collapse
Affiliation(s)
- Borja Ballarín-González
- Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, University of Aarhus, Gustav Wieds Vej 14, 8000 Aarhus C, Denmark
| | - Troels Bo Thomsen
- Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, University of Aarhus, Gustav Wieds Vej 14, 8000 Aarhus C, Denmark
| | - Kenneth Alan Howard
- Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, University of Aarhus, Gustav Wieds Vej 14, 8000 Aarhus C, Denmark
| |
Collapse
|
36
|
Improved biocompatibility of polyethylenimine (PEI) as a gene carrier by conjugating urocanic acid: In vitro and in vivo. Macromol Res 2015. [DOI: 10.1007/s13233-015-3047-8] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
37
|
Kos P, Lächelt U, He D, Nie Y, Gu Z, Wagner E. Dual-Targeted Polyplexes Based on Sequence-Defined Peptide-PEG-Oligoamino Amides. J Pharm Sci 2015; 104:464-75. [DOI: 10.1002/jps.24194] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2014] [Revised: 09/03/2014] [Accepted: 09/09/2014] [Indexed: 01/13/2023]
|
38
|
Chen Z, He Y, Zhang L, Li Y. Enhanced DNA release from disulfide-containing layered nanocomplexes by heparin-electrostatic competition. J Mater Chem B 2015; 3:225-237. [PMID: 32261943 DOI: 10.1039/c4tb01113a] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2024]
Abstract
Polycationic vectors are often used to deliver DNA for cancer therapies, but their inefficiency in releasing DNA from the polyplexes after endosomal escape limits DNA transcription and their efficient application in vivo. In this study, DNA/PEI polyplexes were cross-linked by a reduction-sensitive disulfide bond and then further complexed with electrostatic competitive heparin (HP) and hyaluronidase (HAase)-sensitive hyaluronate (HA) to obtain DNA/PEIS/HA-HP (DPSHA-HP). DPSHA-HP was stable in an extracellular environment (pH = 7.4) and degraded by HAase after targeted HA receptor CD44-mediated cell endocytosis, causing the outer shielding of the nanocomplex to loosen. The resulting partially exposed disulfide-linked DNA/PEI nanocomplexes efficiently ruptured the endosome, facilitating the cleavage of disulfide bonds and the release of DNA/PEI polyplexes into the cytoplasm, where DNA release from the polyplexes was remarkably enhanced due to strong electrostatic competition of HP with PEI. Consequently, DPSHA-HP exhibited excellent DNA transfection of the target cells, better than disulfide cross-linked DNA/PEI (25 kDa) and DNA/PEIS/HA. Moreover, these novel layered nanocomplexes have high efficiency in down-regulating B-cell-specific Moloney murine leukemia virus insertion site 1 (Bmi-1) and exhibit significant inhibition of tumor formation with minimal toxicity in a mouse tumor model.
Collapse
Affiliation(s)
- Zhenzhen Chen
- State Key Laboratory of Applied Organic Chemistry, Key Laboratory of Nonferrous Metals Chemistry and Resources Utilization of Gansu Province, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China.
| | | | | | | |
Collapse
|
39
|
Navarro G, Pan J, Torchilin VP. Micelle-like nanoparticles as carriers for DNA and siRNA. Mol Pharm 2015; 12:301-13. [PMID: 25557580 DOI: 10.1021/mp5007213] [Citation(s) in RCA: 87] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Gene therapy represents a potential efficient approach of disease prevention and therapy. However, due to their poor in vivo stability, gene molecules need to be associated with delivery systems to overcome extracellular and intracellular barriers and allow access to the site of action. Cationic polymeric nanoparticles are popular carriers for small interfering RNA (siRNA) and DNA-based therapeutics for which efficient and safe delivery are important factors that need to be optimized. Micelle-like nanoparticles (MNP) (half micelles, half polymeric nanoparticles) can overcome some of the disadvantages of such cationic carriers by unifying in one single carrier the best of both delivery systems. In this review, we will discuss how the unique properties of MNP including self-assembly, condensation and protection of nucleic acids, improved cell association and gene transfection, and low toxicity may contribute to the successful application of siRNA- and DNA-based therapeutics into the clinic. Recent developments of MNP involving the addition of stimulus-sensitive functions to respond specifically to pathological or externally applied "triggers" (e.g., temperature, pH or enzymatic catalysis, light, or magnetic fields) will be discussed. Finally, we will overview the use of MNP as two-in-one carriers for the simultaneous delivery of different agents (small molecules, imaging agents) and nucleic acid combinations.
Collapse
Affiliation(s)
- Gemma Navarro
- Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University , Boston, Massachusetts 02115, United States
| | | | | |
Collapse
|
40
|
Xie L, Jiang Q, He Y, Nie Y, Yue D, Gu Z. Insight into the efficient transfection activity of a designed low aggregated magnetic polyethyleneimine/DNA complex in serum-containing medium and the application in vivo. Biomater Sci 2015. [DOI: 10.1039/c4bm00317a] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
In vitro fate of designed low aggregated magnetic polyethyleneimine/DNA (MPD-cc) complexes and in vivo study via systemic administration.
Collapse
Affiliation(s)
- Li Xie
- National Engineering Research Center for Biomaterials
- Sichuan University
- Chengdu 610064
- P. R. China
| | - Qian Jiang
- National Engineering Research Center for Biomaterials
- Sichuan University
- Chengdu 610064
- P. R. China
| | - Yiyan He
- National Engineering Research Center for Biomaterials
- Sichuan University
- Chengdu 610064
- P. R. China
| | - Yu Nie
- National Engineering Research Center for Biomaterials
- Sichuan University
- Chengdu 610064
- P. R. China
| | - Dong Yue
- National Engineering Research Center for Biomaterials
- Sichuan University
- Chengdu 610064
- P. R. China
| | - Zhongwei Gu
- National Engineering Research Center for Biomaterials
- Sichuan University
- Chengdu 610064
- P. R. China
| |
Collapse
|
41
|
Wang C, Bao X, Ding X, Ding Y, Abbad S, Wang Y, Li M, Su Y, Wang W, Zhou J. Retracted Article: A multifunctional self-dissociative polyethyleneimine derivative coating polymer for enhancing the gene transfection efficiency of DNA/polyethyleneimine polyplexes in vitro and in vivo. Polym Chem 2015. [DOI: 10.1039/c4py01135j] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A novel coating polymer LPHF is developed for the first time to elevate the transfection efficiency of DP binary polyplexes in vitro and in vivo.
Collapse
|
42
|
Hosseinkhani H, Abedini F, Ou KL, Domb AJ. Polymers in gene therapy technology. POLYM ADVAN TECHNOL 2014. [DOI: 10.1002/pat.3432] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Hossein Hosseinkhani
- Graduate Institute of Biomedical Engineering; National Taiwan University of Science and Technology (Taiwan Tech); Taipei 10607 Taiwan
- Center of Excellence in Nanomedicine; National Taiwan University of Science and Technology (Taiwan Tech); Taipei 10607 Taiwan
- Research Center for Biomedical Devices and Prototyping Production, Research Center for Biomedical Implants and Microsurgery Devices, Graduate Institute of Biomedical Materials and Tissue Engineering, College of Oral Medicine, Taipei Medical University, Department of Dentistry; Taipei Medical University-Shuang Ho Hospital; Taipei 235 Taiwan
| | - Fatemeh Abedini
- Razi Vaccine and Serum Research Institute; Karaj Alborz IRAN
| | - Keng-Liang Ou
- Research Center for Biomedical Devices and Prototyping Production, Research Center for Biomedical Implants and Microsurgery Devices, Graduate Institute of Biomedical Materials and Tissue Engineering, College of Oral Medicine, Taipei Medical University, Department of Dentistry; Taipei Medical University-Shuang Ho Hospital; Taipei 235 Taiwan
| | - Abraham J. Domb
- Institute of Drug Research, The Center for Nanoscience and Nanotechnology, School of Pharmacy-Faculty of Medicine; The Hebrew University of Jerusalem; Jerusalem 91120 Israel
| |
Collapse
|
43
|
Park TE, Singh B, Li H, Lee JY, Kang SK, Choi YJ, Cho CS. Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease. Biomaterials 2014; 38:61-71. [PMID: 25457984 DOI: 10.1016/j.biomaterials.2014.10.068] [Citation(s) in RCA: 90] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2014] [Accepted: 10/19/2014] [Indexed: 01/02/2023]
Abstract
RNA interference (RNAi) holds one of the promising tools for Alzheimer's disease (AD) treatment by directly arresting the causative genes. For successful RNAi therapeutics for AD, limited access of therapeutic genes to the brain needs to be overcome by developing siRNA delivery system that could cross the blood-brain barrier (BBB). Here, we report a non-viral vector, rabies virus glycoprotein (RVG)-modified poly(mannitol-co-PEI) gene transporter (PMT), R-PEG-PMT. The RVG ligand directed the PMT/siRNA complexes toward the brain through binding to nicotinic acetylcholine receptors expressed on BBB. In mechanistic study using in vitro BBB model, we observed that osmotically-active PMT enhanced the receptor-mediated transcytosis by stimulating the caveolar endocytosis. The potential of RNAi therapeutics for AD using R-PEG-PMT/siBACE1 complexes was demonstrated in vitro and in vivo. Our results suggest that R-PEG-PMT is a powerful gene carrier system for brain targeted RNAi therapeutics with synergistic effect of RVG ligand and PMT on well-modulated receptor-mediated transcytosis through BBB.
Collapse
Affiliation(s)
- Tae-Eun Park
- Department of Agricultural Biotechnology & Research Institute for Agriculture and Life Sciences, Seoul National University, Seoul 151-921, South Korea
| | - Bijay Singh
- Department of Agricultural Biotechnology & Research Institute for Agriculture and Life Sciences, Seoul National University, Seoul 151-921, South Korea
| | - Huishan Li
- Department of Agricultural Biotechnology & Research Institute for Agriculture and Life Sciences, Seoul National University, Seoul 151-921, South Korea
| | - Jun-Yeong Lee
- Department of Agricultural Biotechnology & Research Institute for Agriculture and Life Sciences, Seoul National University, Seoul 151-921, South Korea
| | - Sang-Kee Kang
- Institute of Green-Bio Science & Technology, Seoul National University, Pyeongchanggun, Gangwondo 232-916, South Korea
| | - Yun-Jaie Choi
- Department of Agricultural Biotechnology & Research Institute for Agriculture and Life Sciences, Seoul National University, Seoul 151-921, South Korea.
| | - Chong-Su Cho
- Department of Agricultural Biotechnology & Research Institute for Agriculture and Life Sciences, Seoul National University, Seoul 151-921, South Korea.
| |
Collapse
|
44
|
Kodama Y, Ohkubo C, Kurosaki T, Egashira K, Sato K, Fumoto S, Nishida K, Higuchi N, Kitahara T, Nakamura T, Sasaki H. Secure and effective gene delivery system of plasmid DNA coated by polynucleotide. J Drug Target 2014; 23:43-51. [PMID: 25148610 DOI: 10.3109/1061186x.2014.950665] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Polynucleotides are anionic macromolecules which are expected to transfer into the targeted cells through specific uptake mechanisms. So, we developed polynucleotides coating complexes of plasmid DNA (pDNA) and polyethylenimine (PEI) for a secure and efficient gene delivery system and evaluated their usefulness. Polyadenylic acid (polyA), polyuridylic acid (polyU), polycytidylic acid (polyC), and polyguanylic acid (polyG) were examined as the coating materials. pDNA/PEI/polyA, pDNA/PEI/polyU, and pDNA/PEI/polyC complexes formed nanoparticles with a negative surface charge although pDNA/PEI/polyG was aggregated. The pDNA/PEI/polyC complex showed high transgene efficiency in B16-F10 cells although there was little efficiency in pDNA/PEI/polyA and pDNA/PEI/polyU complexes. An inhibition study strongly indicated the specific uptake mechanism of pDNA/PEI/polyC complex. Polynucleotide coating complexes had lower cytotoxicity than pDNA/PEI complex. The pDNA/PEI/polyC complex showed high gene expression selectively in the spleen after intravenous injection into mice. The pDNA/PEI/polyC complex showed no agglutination with erythrocytes and no acute toxicity although these were observed in pDNA/PEI complex. Thus, we developed polynucleotide coating complexes as novel vectors for clinical gene therapy, and the pDNA/PEI/polyC complex as a useful candidate for a gene delivery system.
Collapse
Affiliation(s)
- Yukinobu Kodama
- Department of Hospital Pharmacy, Nagasaki University Hospital , Nagasaki , Japan and
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
LI HAILANG, HE YAXING, GAO QIANHONG, WU GUOZHONG. Folate-polyethylene glycol conjugated carboxymethyl chitosan for tumor-targeted delivery of 5-fluorouracil. Mol Med Rep 2014; 9:786-92. [DOI: 10.3892/mmr.2014.1917] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2013] [Accepted: 12/05/2013] [Indexed: 11/05/2022] Open
|
46
|
Lai WF. In vivonucleic acid delivery with PEI and its derivatives: current status and perspectives. Expert Rev Med Devices 2014; 8:173-85. [DOI: 10.1586/erd.10.83] [Citation(s) in RCA: 65] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
47
|
Cationic Polymers for the Delivery of Therapeutic Nucleotides. POLYSACCHARIDES 2014. [DOI: 10.1007/978-3-319-03751-6_44-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
48
|
Liu J, Liu Z, Luo X, Zong X, Liu J. RAFT Controlled Synthesis of Biodegradable Polymer Brushes on Graphene for DNA Binding and Release. MACROMOL CHEM PHYS 2013. [DOI: 10.1002/macp.201300338] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Jixian Liu
- College of Chemistry, Chemical and Environmental Engineering; Laboratory of Fiber Materials and Modern Textile, the Growing Base for State Key Laboratory; Qingdao University; Qingdao 266071 China
| | - Zhen Liu
- College of Chemistry, Chemical and Environmental Engineering; Laboratory of Fiber Materials and Modern Textile, the Growing Base for State Key Laboratory; Qingdao University; Qingdao 266071 China
| | - Xiong Luo
- College of Chemistry, Chemical and Environmental Engineering; Laboratory of Fiber Materials and Modern Textile, the Growing Base for State Key Laboratory; Qingdao University; Qingdao 266071 China
| | - Xidan Zong
- College of Chemistry, Chemical and Environmental Engineering; Laboratory of Fiber Materials and Modern Textile, the Growing Base for State Key Laboratory; Qingdao University; Qingdao 266071 China
| | - Jingquan Liu
- College of Chemistry, Chemical and Environmental Engineering; Laboratory of Fiber Materials and Modern Textile, the Growing Base for State Key Laboratory; Qingdao University; Qingdao 266071 China
| |
Collapse
|
49
|
Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma. Biomaterials 2013; 34:5149-62. [PMID: 23578555 DOI: 10.1016/j.biomaterials.2013.03.044] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2013] [Accepted: 03/15/2013] [Indexed: 01/28/2023]
Abstract
The therapeutic efficiency of combined chemotherapy and gene therapy on human hepatocellular carcinoma HepG2 cells was investigated using double-walled microspheres that consisted of a poly(D,L-lactic-co-glycolic acid) (PLGA) core surrounded by a poly(L-lactic acid) (PLLA) shell layer and fabricated via the precision particle fabrication (PPF) technique. Here, double-walled microspheres were used to deliver doxorubicin (Dox) and/or chitosan-DNA nanoparticles containing the gene encoding the p53 tumor suppressor protein (chi-p53), loaded in the core and shell phases, respectively. Preliminary studies on chi-DNA nanoparticles were performed to optimize gene transfer to HepG2 cells. The transfection efficiency of chi-DNA nanoparticles was optimal at an N/P ratio of 7. In comparison to the 25-kDa branched polyethylenimine (PEI), chitosan showed no inherent toxicity towards the cells. Next, the therapeutic efficiencies of Dox and/or chi-p53 in microsphere formulations were compared to free drug(s) and evaluated in terms of growth inhibition, and cellular expression of tumor suppressor p53 and apoptotic caspase 3 proteins. Overall, the combined Dox and chi-p53 treatment exhibited enhanced cytotoxicity as compared to either Dox or chi-p53 treatments alone. Moreover, the antiproliferative effect was more substantial when cells were treated with microspheres than those treated with free drugs. High p53 expression was maintained during a five-day period, and was largely due to the controlled and sustained release of the microspheres. Moreover, increased activation of caspase 3 was observed, and was likely to have been facilitated by high levels of p53 expression. Overall, double-walled microspheres present a promising dual anticancer delivery system for combined chemotherapy and gene therapy.
Collapse
|
50
|
Sun VZ, Choe UJ, Rodriguez AR, Dai H, Deming TJ, Kamei DT. Transfection of mammalian cells using block copolypeptide vesicles. Macromol Biosci 2013; 13:539-50. [PMID: 23460310 DOI: 10.1002/mabi.201200383] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2012] [Revised: 12/18/2012] [Indexed: 12/17/2022]
Abstract
An arginine-leucine block copolypeptide (R60 L20 ) is synthesized, which is capable of forming vesicles with controllable sizes, able to transport hydrophilic cargo across the cell membrane, and exhibit relatively low cytotoxicity. The R60 L20 vesicles also possess the ability to deliver DNA into mammalian cells for transfection. Although the transfection efficiency is lower than that of the commercially available transfection agent Lipofectamine 2000, the R60 L20 vesicles are able to achieve transfection with significantly lower cytotoxicity and immunogenicity. This behavior is potentially due to its stronger interaction with DNA which subsequently provides better protection against anionic heparin.
Collapse
Affiliation(s)
- Victor Z Sun
- Department of Bioengineering, University of California, Los Angeles, CA 90095, USA
| | | | | | | | | | | |
Collapse
|